中国の感染症治療市場:抗ウイルス薬、抗真菌薬、抗寄生虫薬

◆英語タイトル:Infectious Disease Treatment Market in China 2016-2020
◆商品コード:IRTNTR9389
◆発行会社(調査会社):Technavio
◆発行日:2016年5月26日
◆ページ数:125
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、中国の感染症治療市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、中国の感染症治療市場規模及び予測、用途別分析、薬剤種類別分析、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About the Infectious Disease Treatment Market in China
Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic.

Technavio’s analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

Technavio’s report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F. Hoffmann-La Roche
• Gilead Sciences
• GSK
• Johnson & Johnson
• Merck
• Pfizer

[Other prominent vendors]
• Achaogen
• Actelion
• Adenovir Pharma
• AstraZeneca
• Bayer
• Biocryst
• Celsus therapeutics
• Cempra
• Eleven Biotherapeutics
• Exoxemis
• Ferrer International
• Griffin Discoveries
• Hexima
• InSite Vision
• Insmed Incorporated
• KaloBios Pharmaceuticals
• Lytix Biopharma
• Meiji Seika Pharma
• Melinta Therapeutics
• Moberg Pharma
• NanoViricides
• Nektar
• NicOx
• NovaBay
• NovaBiotics
• Ocular Therapeutix
• Panoptes Pharma
• Paratek Pharmaceuticals
• Polichem
• PTC Therapeutics
• RedHill
• Shire
• Starpharma Holdings
• Sun Pharma
• Symbiomix
• Tetraphase Pharmaceuticals
• The Medicines Company
• Theravance Biopharma
• Topica Pharmaceuticals
• Vertex Pharmaceuticals
• Viamet Pharmaceuticals

[Market driver]
• Use of combination therapies
• For a full, detailed list, view our report

[Market challenge]
• Development of drug resistant strains
• For a full, detailed list, view our report

[Market trend]
• Emergence of interferon (IFN)-free therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: China – An overview
• Social and economic conditions
• Healthcare reforms
• Healthcare infrastructure

PART 06: Opportunities for global and local vendors
• Local vendors
• Global vendors

PART 07: Pipeline analysis
• AC-170
• DEXTENZA
• Zerbaxa
• Surotomycin
• MK-3415A
• Amikacin Inhale
• CARBAVANCE
• Eravacycline
• Plazomicin
• Delafloxacin
• Solithromycin
• VivaGel
• Arikayce
• Cadazolid
• Ozenoxacin
• TDT 067
• MOB-015
• 1334H
• Auriclosene
• EBI-005
• FST-100
• VT-1161
• Luliconazole solution, 10%
• ME1111
• NP213
• HXP124
• SPL7013
• OPX-1
• AzaSite Xtra (ISV-405)
• GD134

PART 08: Market landscape
• Pharmaceutical market in China
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by application

PART 10: Antibacterial drugs market in China
• MOA
• Market size and forecast

PART 11: Antiviral drugs market in China
• Market size and forecast
• Market segmentation by disease
• Hepatitis C drugs market in China
• Hepatitis B drugs market in China
• HIV drugs market in China

PART 12: Antifungal drugs market in China
• Market size and forecast

PART 13: Antiparasitic drugs market in China

PART 14: Market drivers
• Climatic changes
• Increased exposure to chemicals and pollutants
• Use of combination therapies
• Increased prevalence of infectious diseases
• Increase in awareness

PART 15: Impact of drivers

PART 16: Market challenges
• Counterfeit drugs
• Development of drug-resistant strains
• Patent expiries and generic penetration
• Decreased investments in research
• Increased use of generics and CAMs

PART 17: Impact of drivers and challenges

PART 18: Market trends
• Increase in collaborations and M&A
• Emergence of IFN-free therapies
• Increase in injection drug users

PART 19: Vendor landscape
• Competitive scenario
• F. Hoffmann-La Roche
• Gilead Sciences
• GSK
• Johnson & Johnson
• Merck
• Pfizer
• Other prominent vendors

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: China GDP 2010-2014 ($ trillions)
Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP)
Exhibit 04: Healthcare reforms in China
Exhibit 05: New drug approval (NDA) review process in China
Exhibit 06: New drug approval process in China
Exhibit 07: Drug registration classification and requirements in China
Exhibit 08: Infectious diseases treatment market in China: Pipeline portfolio
Exhibit 09: Pharmaceutical market in China 2015-2020 ($ billions)
Exhibit 10: China pharmaceutical market overview: SWOT analysis
Exhibit 11: Share of infectious diseases market in pharmaceutical market in China 2015
Exhibit 12: Infectious disease treatment market in China 2015-2020 ($ billions)
Exhibit 13: Venues for purchasing anti-infective drugs in China
Exhibit 14: Five forces analysis
Exhibit 15: Infectious disease treatment market in China segmentation by application
Exhibit 16: Infectious disease treatment market in China segmentation by application 2015
Exhibit 17: Infectious disease treatment market in China segmentation by application 2020
Exhibit 18: Infectious disease treatment market in China segmentation by application 2015-2020 ($ billions)
Exhibit 19: Infectious disease treatment market in China segmentation by application 2015-2020 (percentage)
Exhibit 20: Infectious disease treatment market in China 2015-2020
Exhibit 21: YoY growth rate of Infectious disease treatment market in China segments 2015-2020
Exhibit 22: MOA of antibacterial drugs
Exhibit 23: Antibacterial drugs market in China 2015-2020 ($ billions)
Exhibit 24: Segmentation of antibacterial drugs market by chemical class
Exhibit 25: Cephalosporin segmentation by generation of drugs
Exhibit 26: Antibacterial drugs market in China revenue segmentation by chemical class
Exhibit 27: Segmentation of antibacterial drugs market in China by drug origin
Exhibit 28: Antiviral drugs market in China 2015-2020 ($ billions)
Exhibit 29: Segmentation of antiviral drugs market in China by disease 2015
Exhibit 30: Segmentation of antiviral drugs market in China by disease 2020
Exhibit 31: Hepatitis C drugs market in China ($ billions)
Exhibit 32: Hepatitis B drugs market in China 2015-2020 ($ millions)
Exhibit 33: Segmentation of hepatitis B and C market based on MOA
Exhibit 34: HIV drugs market in China ($ millions)
Exhibit 35: HIV drugs market segmentation by drug class 2015
Exhibit 36: Antifungal drugs market in China 2015-2020 ($ millions)
Exhibit 37: Antifungal drugs market in China segmentation by chemical class
Exhibit 38: Antifungal drugs market segmentation by chemical class 2015
Exhibit 39: Antiparasitic drugs market in China ($ millions)
Exhibit 40: Impact of drivers
Exhibit 41: Antibiotic-resistant strains according to the period of development of resistance
Exhibit 42: Impact of drivers and challenges
Exhibit 43: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Pegasys (international) 2013-2015 ($ millions)
Exhibit 44: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Tamiflu (international) 2013-2015 ($ millions)
Exhibit 45: F. Hoffmann-La F. Hoffmann-La Roche: Key takeaways
Exhibit 46: Gilead Sciences: YoY revenue and growth rate of Truvada (international markets) 2013-2015 ($ millions)
Exhibit 47: Gilead Sciences: YoY revenue and growth rate of Atripla (international markets) 2013-2015 ($ millions)
Exhibit 48: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)
Exhibit 49: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)
Exhibit 50: Gilead Sciences: Key takeaways
Exhibit 51: GlaxoSmithKline: Key takeaways
Exhibit 52: Johnson & Johnson: YoY revenue and growth rate of Olysio (International markets) 2013-3015 ($ millions)
Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Prezista (international markets) 2013-3015 ($ millions)
Exhibit 54: Johnson & Johnson: YoY revenue and growth rate of Edurant (international markets) 2013-3015 ($ millions)
Exhibit 55: Johnson & Johnson: Key takeaways
Exhibit 56: Merck: YoY revenue and growth rate of Cancidas (international markets) 2013-2015 ($ millions)
Exhibit 57: Merck: YoY revenue and growth rate of Pegintron (international markets) 2013-2015 ($ millions)
Exhibit 58: Merck: YoY revenue and growth rate of Isentress (international markets) 2013-2015 ($ millions)
Exhibit 59: Merck: YoY revenue and growth rate of Invanz (international markets) 2013-2015 ($ millions)
Exhibit 60: Merck: YoY revenue and growth rate of Noxafil (international markets) 2013-2015 ($ millions)
Exhibit 61: Merck: YoY revenue of Cubicin (international markets) 2013-2015 ($ millions)
Exhibit 62: Merck: Key takeaways
Exhibit 63: Pfizer: YoY revenue and growth rate of Diflucan (emerging markets) 2013-2015 ($ millions)
Exhibit 64: Pfizer: YoY revenue and growth rate of Suplerazon (emerging markets) 2013-2015 ($ millions)
Exhibit 65: Pfizer: YoY revenue and growth rate of Tygacil (Emerging markets) 2013-2015 ($ millions)
Exhibit 66: Pfizer: YoY revenue and growth rate of Vfend (emerging markets) 2013-2015 ($ millions)
Exhibit 67: Pfizer: YoY revenue and growth rate of Zithromax (emerging markets) 2013-2015 ($ millions)
Exhibit 68: Pfizer: YoY revenue and growth rate of Zyvox (emerging markets) 2013-2015 ($ millions)
Exhibit 69: Pfizer: YoY revenue and growth rate of Tygacil (emerging markets) 2013-2015 ($ millions)
Exhibit 70: Pfizer: Key takeaways



【掲載企業】

F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson & Johnson, Merck, Pfizer, Achaogen, Actelion, Adenovir Pharma, AstraZeneca, Bayer, Biocryst, Celsus therapeutics, Cempra, Eleven Biotherapeutics, Exoxemis, Ferrer International, Griffin Discoveries, Hexima, InSite Vision, Insmed Incorporated, KaloBios Pharmaceuticals, Lytix Biopharma, Meiji Seika Pharma, Melinta Therapeutics, Moberg Pharma, NanoViricides, Nektar, NicOx, NovaBay, NovaBiotics, Ocular Therapeutix, Panoptes Pharma, Paratek Pharmaceuticals, Polichem, PTC Therapeutics, RedHill, Shire, Starpharma Holding, Sun Pharma, Symbiomix, Tetraphase Pharmaceuticals, The Medicines Company, Theravance Biopharma, Theravance Biopharma, Topica Pharmaceuticals, Vertex Pharmaceuticals, Viamet Pharmaceuticals.

【レポートのキーワード】

感染症、感染症治療、中国、抗ウイルス薬、抗真菌薬、抗寄生虫薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[中国の感染症治療市場:抗ウイルス薬、抗真菌薬、抗寄生虫薬]販売に関する免責事項
★調査レポート[中国の感染症治療市場:抗ウイルス薬、抗真菌薬、抗寄生虫薬]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆